Nanospect (Human Serum Albumin)

Human serum albumin raises plasma oncotic pressure, pulling water from the interstitial space into the bloodstream. This restores circulating volume, supports blood pressure, and provides a carrier protein for various substances, helping maintain overall fluid balance.

The dose of Nanospect is determined by the prescribing clinician based on the patient’s clinical condition, weight, and laboratory values. Healthcare professionals calculate the required volume to achieve the desired plasma albumin level or hemodynamic effect.

Human serum albumin is a naturally occurring protein, but safety data for Nanospect in pregnancy or lactation are limited. The prescriber should weigh potential benefits against any unknown risks before use in pregnant or nursing individuals.

To order Nanospect, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nanospect (human serum albumin) provides oncotic support, unlike crystalloid solutions that act primarily by expanding extracellular fluid. Compared with synthetic colloids, albumin has a lower risk of coagulopathy and renal impairment, but it is more expensive and requires cold‑chain handling.

Nanospect should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the product to maintain stability and sterility.

Nanospect is administered by intravenous or subcutaneous injection under aseptic conditions. The infusion rate and volume are set by the healthcare provider, who monitors the patient’s vital signs and fluid status throughout the administration.

Serious risks include anaphylactic reactions, volume overload leading to pulmonary edema, acute hemolysis, and rare transmission of infectious agents. Immediate medical attention is required if signs of severe allergy or respiratory distress occur.

Patients with known hypersensitivity to human serum albumin, uncontrolled heart failure, severe renal or hepatic impairment where volume overload is a concern, or those with a history of severe allergic reactions to plasma products should avoid Nanospect unless benefits clearly outweigh risks.